Literature DB >> 34041158

Prevalence of tuberculosis and diabetes comorbidity in patients attending secondary healthcare hospital in south India: A retrospective study.

Dillieswary Ragouraman1, Raman P Priyadharsini2, C Venkatesh3.   

Abstract

BACKGROUND AND OBJECTIVES: Tuberculosis, a communicable disease and diabetes, a non-communicable disease together has a bidirectional relationship toward each other withsignificant morbidity and delayed treatment outcome. Therefore, there is a need to identify the prevalence of both these diseases in a community. A retrospective study was planned to identify the prevalence of both diseases among the patients attending secondary hospitals for 3 years.
METHODS: The study was conducted in the chest diseases department in a secondary care hospital after obtaining approval from the institute ethics committee and RNTCP. The retrospective data in the hospital register was used to identify various parameters. The data for basic demographic characteristics, number of new cases, previously treated cases, pulmonary/extrapulmonary cases, drug resistance cases, and DM/TB cases were entered in Microsoft excel and were analyzed.
RESULTS: The prevalence of TB among the patients attending the chest diseases department was 2.9%, 2.5%, and 3% for the years 2016, 2017, and 2018, respectively. The prevalence of DM/TB ranged between 8.5-11%, which is a lesser range when compared with many other studies. INTERPRETATIONS AND
CONCLUSION: There was no significant difference in the prevalence between the years. The screening of one disease in the presence of the other can reduce the prevalence and improve the prognosis. Copyright:
© 2021 Journal of Family Medicine and Primary Care.

Entities:  

Keywords:  Comorbidity; diabetes; drug resistance; prevalence; tuberculosis

Year:  2021        PMID: 34041158      PMCID: PMC8140231          DOI: 10.4103/jfmpc.jfmpc_1984_20

Source DB:  PubMed          Journal:  J Family Med Prim Care        ISSN: 2249-4863


Introduction

India is one of the highest tuberculosis (TB) burden countries among the eight countries, which contributes to two-thirds of TB cases.[1] As per the World Health Organization (WHO), the incidence of TB has to be reduced to around 4–5% as a part of the end TB strategy.[2] There is a bidirectional relationship between diabetes mellitus (DM) and TB as one increases the risk of the other. DM also affects the course of TB and its treatment.[34] As per the WHO report, people who are immunocompromised are at higher risk of developing TB and diabetes is one such risk factor. DM increases the risk for TB threefold, which urges the need for screening of TB among diabetic patients and vice versa.[4567] It was also estimated that DM is an important risk factor for 15% of TB cases worldwide, and among that 40% of cases were identified in Asian countries like India and China.[8] The proportion of TB was higher among the DM carriers with a value of 13.6% when compared with controls.[9] On the other way, many studies have concluded that glucose tolerance is impaired in TB patients. The cause of glucose intolerance in TB patients is infection-related insulin resistance, which leads to hyperglycemia. TB also causes pancreatitis which may be evident after the screening of diabetes in TB patients. Diabetes reduces cellular immunity which makes the individuals more susceptible to TB. The pharmacokinetics of anti-TB drugs is also affected by the DM and there are also drug interactions like rifampicin inducing the metabolism of antidiabetic drugs.[41011] Drug resistance is another major issue of concern in treating TB and in India, 23% of the new cases have multidrug-resistant tuberculosis (MDR TB).[12] The chances of drug resistance in DM/TB patients increases because the plasma levels of the anti-TB drugs are reduced. The drug isoniazid is prone to induce diabetes by affecting the Krebs cycle and increasing the glucagon secretion.[13] The most commonly treated diseases at the community level include diabetes, hypertension, infections like TB, etc., Owing to high prevalence at the primary care level, it would be desirable and rationale for the primary care physicians to know the deleterious effects of one disease on other's pathogenesis and treatment. There is a high need to identify the prevalence and treat the patients presenting with both DM and TB and to focus on the morbidity imposed by one disease on the other. Thus, the present study aimed to study the prevalence of TB and diabetes comorbidity in patients attending secondary healthcare hospitals and to identify the influence of one disease on the other among the TBDM patients.

Materials and Methods

This study was conducted in a government hospital to identify the prevalence of TB, TB with diabetes, and antituberculosis drug resistance among patients attending the outpatient department for chest diseases. The study was conducted after obtaining approval from the Indian Council of Medical research and the institutional ethics committee 1/8/2019 JIP/lEC/20l9/082. The permissions were obtained from the department of chest diseases and the Revised National TB Control Program (RNTCP), Government hospital. The hospital register was studied in a detailed manner and the data wass entered in an excel sheet. The retrospective data of the patients with the diagnosis of pulmonary TB, extra pulmonary TB, newly treated, previously treated, relapse, default, failure, and antituberculosis drug resistance, werecollected from the register for 3 years from January, 2016 to December, 2018. The patient details (basic demographic characteristics), diagnosis, treatment history, drug susceptibility results, and comorbidities were noted from the records. The difference in the prevalence between the years 2016, 2017, and 2018 was also compared. The impact of diabetes on the course of the disease and treatment outcome was assessed.

Parameters measured

% of patients with TB (new cases) % of patients with TB (previously treated cases) % of patients with pulmonary TB % of patients with extrapulmonary TB % of TB patients with DM % of patients with resistance to drug isoniazid or rifampicin % of patients with resistance to both isoniazid and rifampicin % of patients who discontinued treatment due to the comorbidity of both diseases.

Data analysis

All the data are expressed as percentage. The data are entered in the excel sheet and the percentage of all the parameters is calculated. The statistical analysis of the data was done using statistical package for the social sciences (SPSS) software. The comparison of the percentage of prevalence of TB and DM among the patients between the years was compared using the Chi-square test. A P value < 0.05 was considered statistically significant.

Observation and Results

The basic demographic characteristics of the patient population is listed in Table 1. Around 2.5 to 3 % of the patients were TB patients among those who attended the chest diseases department [Table 2]. The percentage of new cases were decreasing every year [Table 3]. The prevalence of diabetes mellitus and tuberculosis in all three consecutive years ranged between 8.5-10.6%.
Table 1

Basic demographic characteristics of the patient population

201620172018
Age
 <20362124
 20-40807367
 41-60898466
 61-80182021
 >80001
Sex
 Male135127112
 Female887167
Total223198182
Table 2

Prevalence of TB among the patients attending the hospital in the years 2016, 2017, and 2018

201620172018
Total number of patient who attended chest diseases department751979116054
Total TB cases223198182
Prevalence of TB among the population who attend the chest diseases department.2.96%2.50%3%
Table 3

Comparison of the percentages of various parameters between the years 2016, 2017, and 2018

Parameter201620172018
Number of new cases (% of new cases)196 (87.90%)178 (89.90%)154 86.00%)
Number of previously treated (% of previously treated)27 (12.10%)20 (10.10%)25 (14.00%)
Number of pulmonary TB (% of pulmonary TB)159 (71.30%)139 (70.20%)128 (71.50%)
Number of extra pulmonary TB (% of extra pulmonary TB)64 (28.70%)59 (29.80%)51 (28.50%)
Number of TB patients with DM (% ofTB patients with DM)19 (8.50%)21 (10.60%)16 (8.90%)
Number of patients with H or R resistance (% of resistance to H or R)4 (1.80%)5 (2.50%)1 (0.55%)
% of resistance to H and R4 (1.80%)1 (0.50%)4 (2.20%)
% of patients who discontinued treatment due to the comorbidity of both diseases1 (0.4%)--
Basic demographic characteristics of the patient population Prevalence of TB among the patients attending the hospital in the years 2016, 2017, and 2018 Comparison of the percentages of various parameters between the years 2016, 2017, and 2018

Discussion

The present study shows that the prevalence of the DM among TB patients is 8.5%, 10.6%, and 8.9% for the years 2016, 2017, and 2018, respectively [Figure 1]. Our study results are comparable with the study reported by Gil et al. in which the prevalence of diabetes among tuberculosis patients in TB endemic countries like South Africa, Peru, Romania, and Indonesia was 12.5%.[14] The study also reported that patients with dual diseases had a higher incidence of cardiovascular diseases and increased morbidity. The prevalence is less when compared with other studies reported by Nagar et al. in Bhopal, Mansuri et al. in Ahmedabad, and Jiménez-Corona, et al. in Mexico[151617] The global prevalence of diabetes among TB patients is identified to be 15.3% from a systematic review of 200 studies and our study shows a lesser value compared to that study.[18] The prevalence in our study increased to 10.6% in the year 2017 and decreased in the subsequent year. The reason for this trend of rise and fall of prevalence cannot be well explained but there exists a range of 8–11% over 3 years and there is no significant difference in the prevalence when all 3 years are compared.
Figure 1

Difference in the prevalence of DM among TB patients in the years 2016, 2017, and 2018: The Chi-square test is used. P value = 0.74 P value > 0.05 indicates no significant difference in the prevalence among 3 years

Difference in the prevalence of DM among TB patients in the years 2016, 2017, and 2018: The Chi-square test is used. P value = 0.74 P value > 0.05 indicates no significant difference in the prevalence among 3 years In contrast to the literature, most of the TB patients with diabetes were cured and completed the treatment. The percentages of the cured patients among DM/TB patients are 52.6%, 80.9%, and 56.25% in the years 2016, 2017, and 2018, respectively. A systematic review of 59 studies conducted in the Middle East showed that there is no or little difference in the clinical presentation between DM/TB and nondiabetic TB patients whereas the microbiological response to drugs is delayed in DM/TB patients.[19] However, the result of the present study differs from the concept as more than 50% of patients are cured. Our study indicates that diabetes did not have much impact on the cure following anti-TB treatment since more than 50% had attained cure. The other valid point is that since the data is analyzed from the hospital register, certain information about the time of diagnosis of diabetes, the drugs used for diabetic treatment, the severity of diabetes, the impact of diabetes on tuberculosis is lacking and so there is a difficulty to explain completely. Our study shows that the number of deaths among diabetes and TB patients is two out of 19 and one out of 16 in the years 2016 and 2018, respectively. The cause of death is not mentioned in the register and this is one limitation of the study. The mortality due to diabetes among tuberculosis patients is also not established in the study conducted in Mexico by Jimenez-Corona et al.[20] In the year 2017, out of five patients with isoniazid and rifampicin resistance, three patients were diabetic. In the other 2 years, there is no association of drug resistance with diabetes [Table 4]. The risk of rifampicin resistance is increased threefold when there is diabetes comorbidity.[21] The role of drug resistance due to diabetes is not much appreciated in the present study.
Table 4

Prevalence of DM among TB patients

201620172018
Number of cases of DM + TB19 (100%)21 (100%)16 (100%)
% of cases of DM and TB8.5%10.6%8.9%
Distribution of DM + TB cases
 Cured10 (52.6%)17 (80.9%) (including 2 resistance cases)9 (56.25%)
 Default1 (5.26%)--
 Failure1 (5.26%)13 (18.7%)
 Resistance-3-
 Death2 (10.5%)-1
 Completed the treatment5 (26.3%)2 (9.5%)3 (18.7%)
Prevalence of DM among TB patients The prevalence of TB among the patients attending the chest diseases department is 2.9%, 2.5%, and 3% for the years 2016, 2017, and 2018, respectively. The number of TB cases (both new cases and previously treated) is decreasing year by year with values of 223, 198, and 182 in the years 2016, 2017, and 2018, respectively. Males were mostly affected compared to females [Table 1]. The new cases and the pulmonary cases are higher in number compared to the previously treated and the extra pulmonary cases, respectively. It is a known fact that diabetes contributes to the risk of TB mortality and morbidity through many mechanisms such asprogression from latent TB to active TB, late sputum conversion during treatment, treatment failure, etc., The major proposed mechanism for the deterioration is diabetic immunopathy with fewer levels of IL-10, an anti-inflammatory cytokine in TBDM patients.[2223]

Strength

The study compares the prevalence of TB, TB, and DM over three subsequent years, which gives an idea about the trend in the prevalence of both diseases.

Limitation

The retrospective data from the hospital register is used for analysis and certain information such as the history, lab investigations, and the disease status could not be identified. The reason for the death of the patients could not be identified in this study.

Conclusion

The prevalence of TB among the patients attending the chest diseases department is 2.9%, 2.5%, and 3% for the years 2016, 2017, and 2018, respectively. In the present study, we found that the prevalence of DM among TB patients over 3 years ranged between 8.5–11% and it is less when compared with many other studies. There was a decrease in the total number of TB cases every year but there was an increase in the percentage of new cases every year. The increased efforts in screening and treatment of both diseases can further reduce the prevalence in a community and good knowledge about the bidirectional relationship between the communicable and noncommunicable diseases can encourage the physicians at the primary care level to manage both efficiently.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  18 in total

1.  The association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes.

Authors:  Roshani N Sanghani; Zarir F Udwadia
Journal:  Thorax       Date:  2013-03       Impact factor: 9.139

2.  Diabetes Mellitus Among Pulmonary Tuberculosis Patients From 4 Tuberculosis-endemic Countries: The TANDEM Study.

Authors:  Cesar Ugarte-Gil; Bachti Alisjahbana; Katharina Ronacher; Anca Lelia Riza; Raspati C Koesoemadinata; Stephanus T Malherbe; Ramona Cioboata; Juan Carlos Llontop; Leanie Kleynhans; Sonia Lopez; Prayudi Santoso; Ciontea Marius; Katerine Villaizan; Rovina Ruslami; Gerhard Walzl; Nicolae Mircea Panduru; Hazel M Dockrell; Philip C Hill; Susan Mc Allister; Fiona Pearson; David A J Moore; Julia A Critchley; Reinout van Crevel
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

Review 3.  Tuberculosis and diabetes: from bench to bedside and back.

Authors:  N Martinez; H Kornfeld
Journal:  Int J Tuberc Lung Dis       Date:  2019-06-01       Impact factor: 2.373

4.  Association between diabetes and tuberculosis: case-control study.

Authors:  Susan Martins Pereira; Gleide Santos de Araújo; Carlos Antônio de Souza Teles Santos; Maeli Gomes de Oliveira; Maurício Lima Barreto
Journal:  Rev Saude Publica       Date:  2016-12-22       Impact factor: 2.106

Review 5.  Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden.

Authors:  Chunlan Zheng; Minhui Hu; Feng Gao
Journal:  Glob Health Action       Date:  2017       Impact factor: 2.640

6.  A study on prevalence of diabetes and associated risk factors among diagnosed tuberculosis patients registered under Revised National Tuberculosis Control Programme in Bhopal District.

Authors:  Vivek Nagar; Devendra Gour; Dinseh Kumar Pal; Akash Ranjan Singh; Ankur Joshi; Lokendra Dave
Journal:  J Family Med Prim Care       Date:  2018 Jan-Feb

7.  Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity.

Authors:  Nathella Pavan Kumar; Kiyoshi F Fukutani; Bruno B Andrade; Hardy Kornfeld; Basavaradhya S Shruthi; Thabata Alves; Paulo S Silveira-Mattos; Michael S Rocha; Kim West; Mohan Natarajan; Vijay Viswanathan; Subash Babu
Journal:  Elife       Date:  2019-07-04       Impact factor: 8.140

8.  Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes.

Authors:  María Eugenia Jiménez-Corona; Luis Pablo Cruz-Hervert; Lourdes García-García; Leticia Ferreyra-Reyes; Guadalupe Delgado-Sánchez; Miriam Bobadilla-Del-Valle; Sergio Canizales-Quintero; Elizabeth Ferreira-Guerrero; Renata Báez-Saldaña; Norma Téllez-Vázquez; Rogelio Montero-Campos; Norma Mongua-Rodriguez; Rosa Areli Martínez-Gamboa; José Sifuentes-Osornio; Alfredo Ponce-de-León
Journal:  Thorax       Date:  2012-12-18       Impact factor: 9.102

9.  Diabetes and tuberculosis: a review of the role of optimal glycemic control.

Authors:  Asfandyar Khan Niazi; Sanjay Kalra
Journal:  J Diabetes Metab Disord       Date:  2012-12-20

10.  Isoniazid induced childhood diabetes: A rare phenomenon.

Authors:  Gutch Manish; Gupta Kumar Keshav; Razi Mohd Syed; Kumar Sukriti; Gupta Abhinav
Journal:  J Basic Clin Pharm       Date:  2015-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.